In MYC-overexpressing TNBC patient-derived xenografts, researchers have used metabolomics analysis to identify a lipid metabolism gene signature and they have shown that pharmacological inhibition of fatty acid oxidation (FAO) can decrease tumor growth [43]. This evidence concerns the gene MYC and neoplasm.